FAQ/Help |
Calendar |
Search |
Today's Posts |
11-15-2007, 05:44 PM | #1 | |||
|
||||
Senior Member
|
http://tishcon.com/
"Tishcon obtains Orphan Drug Designation for Ubiquinol from the US FDA. The designation is for the use of Ubiquinol in the treatment of Huntington's disease. " Above from Tishcon web site. If a drug has obtained FDA orphan drug status, one's physician may order it, even for "off label" use--ie one need not have huntington's in order to receive a prescription for the drug. Maybe some insurance companies would cover the cost of the supplement--even partial coverage would help considering the doses used in PD. Worth a try--will ask husband's MDS at December appointment.
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here — it's just not very evenly distributed. William Gibson |
|||
Reply With Quote |
11-16-2007, 10:39 AM | #2 | |||
|
||||
Senior Member
|
update on coq10/ubiquinone preparation (labeled "Mitoq" in article)
Antioxid Redox Signal. 2007 Nov 13; [Epub ahead of print] Is Antioxidant Potential of the Mitochondrial Targeted Ubiquinone Derivative MitoQ Conserved in Cells Lacking mtDNA? Lu C, Zhang D, Whiteman M, Armstrong JS. Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Republic of Singapore. MitoQ has been developed as a mitochondrial targeted antioxidant for diseases associated with oxidative stress. Here we show that MitoQ blocks the generation of reactive oxygen species (ROS) and mitochondrial protein thiol oxidation, and preserves mitochondrial function and ultrastructure after glutathione (GSH) depletion. Furthermore, the antioxidant effect of MitoQ is conserved in cells lacking mitochondrial DNA, indicating that its antioxidant properties do not depend on a functional electron transport chain (ETC). Our results elucidate the antioxidant mechanism of MitoQ and suggest that it may be a useful therapeutic for disorders associated with a dysfunctional ETC and increased ROS production. PMID: 17999633 [PubMed - as supplied by publisher]
__________________
In the last analysis, we see only what we are ready to see, what we have been taught to see. We eliminate and ignore everything that is not a part of our prejudices. ~ Jean-Martin Charcot The future is already here — it's just not very evenly distributed. William Gibson |
|||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
inhaled apomorphine approved via orphan status in the EU | Parkinson's Disease | |||
Knopp Neurosciences Receives Orphan Designation For KNS-760704 For Treatment Of ALS | ALS News & Research | |||
Food Study: CoQ10 Coenzyme Q10 or ubiquinone | Gluten Sensitivity / Celiac Disease | |||
Trophos Granted Orphan Drug Status For Tro19622 | ALS News & Research | |||
Trophos Granted Orphan Drug Status for TRO19622 | ALS News & Research |